纳武利尤单抗在既往接受治疗或未接受治疗的晚期黑色素瘤患者中的暴露-反应分析。 - Suppr

Suppr

超能文献

Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.

作者信息

Bajaj Gaurav, Gupta Manish, Feng Yan, Statkevich Paul, Roy Amit

机构信息

Bristol-Myers Squibb, Princeton, NJ, USA.

出版信息

J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11.

DOI:10.1002/jcph.962

PMID:28800166

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5697692/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/435e/5697692/c032873205f1/JCPH-57-1527-g001.jpg

相似文献

Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.纳武利尤单抗在既往接受治疗或未接受治疗的晚期黑色素瘤患者中的暴露-反应分析。

J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11.

A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.一种机器学习方法，用于识别与晚期黑色素瘤患者纳武利尤单抗清除相关的预后细胞因子特征。

Clin Pharmacol Ther. 2020 Apr;107(4):978-987. doi: 10.1002/cpt.1724. Epub 2019 Dec 19.

Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.结节性红斑作为纳武单抗诱导的类结节病反应的初始表现。

J Cutan Med Surg. 2018 Nov/Dec;22(6):627-629. doi: 10.1177/1203475418776934. Epub 2018 May 17.

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.纳武利尤单抗联合立体定向放疗治疗转移性或局部晚期不可切除黑色素瘤的 2 期临床试验。

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):828-835. doi: 10.1016/j.ijrobp.2019.03.041. Epub 2019 Apr 3.

Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.在一名黑色素瘤患者接受纳武单抗治疗期间，无晕良性黑素细胞痣中免疫反应的诱导。

JAMA Dermatol. 2017 Aug 1;153(8):832-834. doi: 10.1001/jamadermatol.2017.0615.

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.接受纳武单抗治疗的原发性肺黑色素瘤中的双细胞减少症。

Intern Med. 2019 Mar 15;58(6):827-831. doi: 10.2169/internalmedicine.1011-18. Epub 2018 Nov 19.

Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab.纳武利尤单抗治疗晚期黑色素瘤患者外周血特征波动。

J Dermatol. 2018 Dec;45(12):1452-1455. doi: 10.1111/1346-8138.14643. Epub 2018 Sep 11.

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.纳武利尤单抗和伊匹单抗颅内抗肿瘤反应：药效学和药代动力学视角，范围系统性综述。

BMC Cancer. 2019 May 30;19(1):519. doi: 10.1186/s12885-019-5741-y.

Predicting marker for early progression in unresectable melanoma treated with nivolumab.预测不可切除性黑色素瘤经纳武利尤单抗治疗后早期进展的标志物。

Int J Clin Oncol. 2019 Mar;24(3):323-327. doi: 10.1007/s10147-018-1345-9. Epub 2018 Aug 30.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.纳武利尤单抗和伊匹单抗联合治疗晚期黑色素瘤患者的汇总分析安全性概况。

J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.

引用本文的文献

Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab.纳武单抗单药治疗及与伊匹单抗联合治疗的模型指导免疫原性评估

AAPS J. 2025 Apr 25;27(4):79. doi: 10.1208/s12248-025-01069-y.

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.晚期黑色素瘤患者的身体成分与检查点抑制剂治疗结果：一项多中心队列研究

J Natl Cancer Inst. 2025 Jun 1;117(6):1245-1252. doi: 10.1093/jnci/djaf039.

Navigating Recent Changes in Dosing Information: Dynamics of FDA-Approved Monoclonal Antibodies in Post-Marketing Realities.应对剂量信息的近期变化：上市后实际情况中FDA批准的单克隆抗体动态

Clin Transl Sci. 2025 Jan;18(1):e70125. doi: 10.1111/cts.70125.

Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.抗体药物清除：免疫检查点抑制剂疗效的一个未充分研究的标志物。

Clin Cancer Res. 2024 Mar 1;30(5):942-958. doi: 10.1158/1078-0432.CCR-23-1683.

Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.基于儿科模型的剂量优化，使用黑色素瘤中纳武单抗和纳武单抗联合伊匹单抗的汇总暴露-反应安全性分析。

CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):168-179. doi: 10.1002/psp4.13070. Epub 2023 Nov 6.

Melanoma: An immunotherapy journey from bench to bedside.黑色素瘤：从实验室到临床的免疫治疗之旅。

Cancer Treat Res. 2022;183:49-89. doi: 10.1007/978-3-030-96376-7_2.

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?免疫检查点靶向抗体：剂量和方案优化的空间？

J Hematol Oncol. 2022 Jan 15;15(1):6. doi: 10.1186/s13045-021-01182-3.

Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.雷莫芦单抗在 RANGE 中的暴露-反应关系，这是一项在铂类药物难治性晚期尿路上皮癌中进行的随机 III 期试验。

Br J Clin Pharmacol. 2022 Jul;88(7):3182-3192. doi: 10.1111/bcp.15233. Epub 2022 Feb 7.

Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.纳武利尤单抗辅助治疗黑色素瘤的暴露-反应分析支持改变剂量。

CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):748-759. doi: 10.1002/psp4.12642. Epub 2021 Jun 11.

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?肺癌中免疫检查点抑制剂的延长给药间隔策略：它能在新冠疫情期间持续有效吗？

Front Oncol. 2020 Jun 23;10:1193. doi: 10.3389/fonc.2020.01193. eCollection 2020.

本文引用的文献

Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.评估 240mg 平剂量与 3mg/kg 剂量方案相比，在晚期肿瘤患者中使用纳武利尤单抗的获益-风险概况。

Ann Oncol. 2017 Aug 1;28(8):2002-2008. doi: 10.1093/annonc/mdx235.

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.纳武利尤单抗的时变清除率与疾病动态的关联及其对暴露-反应分析的影响

Clin Pharmacol Ther. 2017 May;101(5):657-666. doi: 10.1002/cpt.656. Epub 2017 Mar 22.

Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.纳武单抗在实体瘤患者中的基于模型的群体药代动力学分析。

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):58-66. doi: 10.1002/psp4.12143. Epub 2016 Dec 26.

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.癌症免疫治疗暴露-反应关系的定量表征：以纳武利尤单抗治疗晚期黑色素瘤患者为例

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):40-48. doi: 10.1002/psp4.12133. Epub 2016 Dec 26.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.纳武利尤单抗联合伊匹木单抗作为晚期非小细胞肺癌的一线治疗方案（CheckMate 012）：一项开放标签的1期多队列研究结果

Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.

Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.非小细胞肺癌中PD-1/PD-L1检查点抑制剂的伴随诊断检测

Expert Rev Mol Diagn. 2016;16(2):131-3. doi: 10.1586/14737159.2016.1117389. Epub 2015 Nov 27.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌

N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较

N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较

N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验